The Daily Folgen

Last week, after the Air Force shot down a Chinese surveillance balloon, examination of its wreckage revealed that it could not only take images, but also scoop up radio and cellphone communications. The balloon, the U.S. military said, was part of a bigger global program by China to collect information about military operations.Since then the U.S. has shot down three other objects from the skies over North America — apparently without knowing much about them.Guest: Julian E. Barnes, a national security reporter for The New York Times.Background reading: The U.S. and Canada are investigating three unidentified flying objects shot down over North America in recent days. Militaries have adjusted radars to try to spot more incursions.A timeline of the unidentified flying objects that have been brought down this month.Here is what we know about the objects and the Chinese spy balloon.For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.  Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.

Amid growing threats from rivals like China, the United States military is determined to invest in new forms of defense and abandon those that no longer meet its needs.On that list: a combat ship rife with flaws. But getting rid of the ship has proved unexpectedly difficult.Guest: Eric Lipton, an investigative reporter for The New York Times.Background reading: After years of crippling problems and a changing mission, the Navy pushed to retire nine of its newest ships. Then the lobbying started.For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.  Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.

Menopausal hormone therapy was once the most commonly prescribed treatment in the United States. In the late 1990s, some 15 million women a year were receiving a prescription for it. But in 2002, a single study, its design imperfect, found links between hormone therapy and elevated health risks for women of all ages. Panic set in; in one year, the number of prescriptions plummeted.Hormone therapy carries risks, to be sure, as do many medications that people take to relieve serious discomfort, but dozens of studies since 2002 have provided reassurance that for healthy women under 60 whose hot flashes are troubling them, the benefits of taking hormones outweigh the risks. The treatment’s reputation, however, has never fully recovered, and the consequences have been wide-reaching.About 85 percent of women experience menopausal symptoms. Rebecca Thurston, a professor of psychiatry at the University of Pittsburgh who studies menopause, believes that, in general, menopausal women have been underserved — an oversight that she considers one of the great blind spots of medicine.“It suggests that we have a high cultural tolerance for women’s suffering,” Thurston said. “It’s not regarded as important.”To hear more stories from publications like The New York Times, download Audm for iPhone or Android.  Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.